The task of meeting the “Safety Features” requirements of the EU Falsified Medicines Directive (EU-FMD) is daunting. Serialisation expert, Christoph Krähenbühl, 3C Integrity, deconstructs the final draft Delegated Act to summarise the key actions required by pharma manufacturers in implementing serialisation programmes
Christoph Krähenbühl, 3C Integrity, explains that by early 2019, every pharma manufacturer that supplies Europe must be in in full compliance with the EU-FMD